公开(公告)号：US20120177735A1

公开(公告)日：2012-07-12

申请号：US13063462

申请日：2010-09-29

Applicant: Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

Inventor： Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

IPC: A61K31/445 ,  A61P25/28 ,  A61P25/00 ,  A61K9/00 ,  A61K9/44

CPC classification number: A61K45/06 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078 ,  A61K31/13 ,  A61K31/445 ,  A61K2300/00

Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.

Abstract translation: 本文公开了含有用于治疗神经变性疾病的立即释放和缓释药物的口服剂量制剂。 口服剂量制剂中的立即释放药物是乙酰胆碱酯酶抑制剂（AChEI），溶解速率在60分钟内释放超过80％的AChEI; 持续释放药物是在12小时内释放超过80％的美金刚的溶解速率的美金刚。

公开(公告)号：US20110171302A1

公开(公告)日：2011-07-14

申请号：US13071520

申请日：2011-03-25

Applicant: Guang-Tzuu SHANE ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Hui-Ling Tsai ,  Pei-Chen Tsai

Inventor： Guang-Tzuu SHANE ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Hui-Ling Tsai ,  Pei-Chen Tsai

IPC: A61K9/44 ,  A61K31/445 ,  A61K9/50 ,  A61K9/26 ,  A61P25/28

CPC classification number: A61K45/06 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078 ,  A61K31/13 ,  A61K31/445 ,  A61K2300/00

Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.

Abstract translation: 本文公开了一种用含有缓释和立即释放药物的口服剂量制剂治疗患有与中枢神经系统相关疾病的患者的方法。 口服剂量制剂中的持续释放药物是美金刚，并且在约10-45小时的平均Tmax期间，该制剂在约10-24ng / mL的范围内提供了美金刚的平均血液C max值。 口服剂量制剂中的立即释放药物是乙酰胆碱酯酶抑制剂（AChEI），并且该制剂在约12-38ng / mL范围内提供AChEI的平均血液C max，平均Tmax小于约4 小时。

公开(公告)号：US08815288B2

公开(公告)日：2014-08-26

申请号：US13063462

申请日：2010-09-29

Applicant: Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

Inventor： Huai-Cheng Lee ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Rong Jin Lin

IPC: A61K9/44

CPC classification number: A61K45/06 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078 ,  A61K31/13 ,  A61K31/445 ,  A61K2300/00

Abstract: Disclosed herein is an oral dosage formulation that contains both immediate-release and sustained release drugs for treating neurodegenerative disorders. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI) with a dissolution rate of releasing more than 80% of the AChEI within 60 min; and the sustained-release drug is memantine with a dissolution rate of releasing more than 80% of memantine within 12 hours.

Abstract translation: 本文公开了含有用于治疗神经变性疾病的立即释放和缓释药物的口服剂量制剂。 口服剂量制剂中的立即释放药物是乙酰胆碱酯酶抑制剂（AChEI），溶解速率在60分钟内释放超过80％的AChEI; 持续释放药物是在12小时内释放超过80％的美金刚的溶解速率的美金刚。

公开(公告)号：US08802143B2

公开(公告)日：2014-08-12

申请号：US13071520

申请日：2011-03-25

Applicant: Guang-Tzuu Shane ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Hui-Ling Tsai ,  Pei-Chen Tsai

Inventor： Guang-Tzuu Shane ,  Chien-Fen Chen ,  Chuen-Lin Din ,  Hui-Ling Tsai ,  Pei-Chen Tsai

IPC: A61K9/44

CPC classification number: A61K45/06 ,  A61K9/1635 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/5078 ,  A61K31/13 ,  A61K31/445 ,  A61K2300/00

Abstract: Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level Cmax of the memantine in a range of about 10-24 ng/mL during an average Tmax of about 10-45 hours. The immediate-release drug in the oral dosage formulation is an acetylcholinesterase inhibitor (AChEI), and the formulation provides an average blood level Cmax of the AChEI in a range of about 12-38 ng/mL during an average Tmax of less than about 4 hours.

Abstract translation: 本文公开了一种用含有缓释和立即释放药物的口服剂量制剂治疗患有与中枢神经系统相关疾病的患者的方法。 口服剂量制剂中的持续释放药物是美金刚，并且在约10-45小时的平均Tmax期间，该制剂在约10-24ng / mL的范围内提供了美金刚的平均血液C max值。 口服剂量制剂中的立即释放药物是乙酰胆碱酯酶抑制剂（AChEI），并且该制剂在约12-38ng / mL范围内提供AChEI的平均血液C max，平均Tmax小于约4 小时。